Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

NEXGEL Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Adam Levy

İcra Kurulu Başkanı

US$442.1k

Toplam tazminat

CEO maaş yüzdesi	73.5%
CEO görev süresi	5.1yrs
CEO sahipliği	4.5%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.1yrs

Son yönetim güncellemeleri

Recent updates

NexGel: Old Wine In A New Bottle

Jan 30

CEO Tazminat Analizi

Adam Levy'un ücretlendirmesi NEXGEL'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$3m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$442k	US$325k	-US$3m
Sep 30 2023	n/a	n/a	-US$3m
Jun 30 2023	n/a	n/a	-US$3m
Mar 31 2023	n/a	n/a	-US$4m
Dec 31 2022	US$450k	US$300k	-US$5m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$6m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$306k	US$180k	-US$4m
Sep 30 2021	n/a	n/a	-US$3m
Jun 30 2021	n/a	n/a	-US$3m
Mar 31 2021	n/a	n/a	-US$2m
Dec 31 2020	US$226k	US$143k	-US$2m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$1m
Mar 31 2020	n/a	n/a	-US$2m
Dec 31 2019	US$129k	US$40k	-US$2m

Tazminat ve Piyasa: Adam 'nin toplam tazminatı ($USD 442.10K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 677.23K ).

Tazminat ve Kazançlar: Adam 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Adam Levy (61 yo)

5.1yrs

Görev süresi

US$442,100

Tazminat

Mr. Adam R. Levy has been Chief Executive Officer and President of NEXGEL, Inc. since September 10, 2019 and had been its Chief Financial Officer since December 31, 2019 until June 1, 2021. He serves as Di...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Adam Levy	CEO, President & Director	3.1yrs	US$442.10k	4.51% $ 751.6k
Jerome Zeldis	Independent Director & Chairman of Scientific Advisory Board	4.5yrs	US$30.75k	1.52% $ 253.4k
Nachum Stein	Independent Director	5.1yrs	US$30.75k	6.97% $ 1.2m
Scott Henry	Independent Director	1.8yrs	US$30.75k	2.15% $ 358.5k
Stephen Brigido	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Steven Glassman	Independent Chairman	3.6yrs	US$30.75k	2.14% $ 356.8k
Stephen Banco	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Neil Chesen	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok
Leonard Nelson	Member of Scientific Advisory Board	2.1yrs	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NXGL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.1 yıldır).

NEXGEL Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

NEXGEL, Inc., Annual General Meeting, Jun 17, 2024

NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024

NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors

NEXGEL, Inc. Announces Directorate and Committee Changes

Nexgel Appoints Scott Henry, to Board of Directors and Audit Committee

High number of new and inexperienced directors

Recent updates

NEXGEL, Inc. Reiterates Revenue Guidance for the Third Quarter and Fourth Quarter of 2024

NEXGEL, Inc. has filed a Follow-on Equity Offering in the amount of $1.11 million.

NEXGEL, Inc. to Report Q2, 2024 Results on Aug 14, 2024

New minor risk - Share price stability

NEXGEL, Inc. and Innovative Optics US Initiate Institutional Review Board Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal

NEXGEL, Inc. Provides Preliminary Revenue Guidance for the Second, Third and Fourth Quarter of 2024

Price target decreased by 14% to US$6.00

NEXGEL, Inc. to Report Q1, 2024 Results on May 13, 2024

NEXGEL, Inc., Annual General Meeting, Jun 17, 2024

NEXGEL, Inc. announced delayed annual 10-K filing

Forecast breakeven date pushed back to 2026

NEXGEL, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. has filed a Follow-on Equity Offering.

NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024

NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

NEXGEL, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target increased by 20% to US$6.00

New major risk - Market cap size

New major risk - Market cap size

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

NEXGEL, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Consensus revenue estimates increase by 62%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NEXGEL, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

NEXGEL, Inc. Announces Directorate and Committee Changes

Nexgel Appoints Scott Henry, to Board of Directors and Audit Committee

Forecast to breakeven in 2025

NEXGEL, Inc. Launches Turfguard to Treat Painful Turf Burns and Protect Sports-Related Wounds

NEXGEL, Inc. (NasdaqCM:NXGL) announces an Equity Buyback for $0.5 million worth of its shares.

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NEXGEL, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NEXGEL, Inc. Reports Positive Results from Proof-Of-Concept Study for Its Diclofenac Hydrogel Pain Treatment

Nexgel, Inc. Develops New Hydrogel Patch to Treat Amblyopia

NEXGEL, Inc. Announces SAGE Journals Publishes New Data Revealing SilverSeal Hydrogel Dressing Improves Postsurgical Scarring

NEXGEL, Inc. Announces Scientific Advisory Board Appointments

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NEXGEL, Inc. to Report Q2, 2022 Results on Aug 10, 2022

NEXGEL Launches Medagel Hydroliner Pro Pads for Eyelash Protection During Cosmetic Extensions Service

NEXGEL, Inc., Annual General Meeting, Aug 30, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

NEXGEL, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

NexGel: Old Wine In A New Bottle

NEXGEL, Inc. Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch

NEXGEL, Inc. has completed an IPO in the amount of $14.235131 million.

High number of new and inexperienced directors

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş